US4806523A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treating inflammation
Assignee: Celtrix Pharmaceuticals Inc
•
Filing: 1986-03-06
•
Granted: 1989-02-21
•
Expires: 2006-03-06
Abstract
Abstract Inflammation, acute and/or chronic, is treated with a CIF (TGF-β). The CIF may be administered locally or symstemically, depending upon the indication, and does not require coadministraion of activator or cofactor for efficacy.
Inventors
- 👤 Hanne Bentz
- 👤 Larry Ellingsworth
- 👤 Rosa Armstrong
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 04:03
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/495; A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1841; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61P; A61P29/00; A61P37/00; A61P7/00; C07K14/51; C07K16/00; C07K16/18; C07K16/22; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/84; Y10S930/00; Y10S930/01; Y10S930/12
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
49 words
A method of treating a patient for inflammation comprising administering an anti-inflammatorily effective amount of a CIF to the patient, wherein said CIF is a homodimer whose chains each have (a) the following partial N-terminal amino acid sequence: Ala-Leu-ASp-Thr-Asn-Tyr-Cys-Phe-Ser-Ser-Thr-Glu-Lys-Asn-Cys-Cys-Val-Arg-Gln-Leu-Tyr-Ile-Asp-Phe-Arg-Lys-Asp-Leu-Gly-Trp-, or (b) the following partial N-terminal amino acid sequence: Ala-Leu-Asp-Ala-Ala-Tyr-Cys-Phe-ARg-Asn-Val-Gln-Asp-Asn-Cys-Cys-Leu-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Lys-Arg-Asp-Leu-Gly-Trp.
Claim 2
Independent Claim
49 words
A method of treating a patient for inflammation comprising administering an anti-inflammatorily effective amount of a CIF to the patient, wherein said CIF is a homodimer whose chains each have (a) the following partial N-terminal amino acid sequence: Ala-Leu-ASp-Thr-Asn-Tyr-Cys-Phe-Ser-Ser-Thr-Glu-Lys-Asn-Cys-Cys-Val-Arg-Gln-Leu-Tyr-Ile-Asp-Phe-Arg-Lys-Asp-Leu-Gly-Trp-, or (b) the following partial N-terminal amino acid sequence: Ala-Leu-Asp-Ala-Ala-Tyr-Cys-Phe-ARg-Asn-Val-Gln-Asp-Asn-Cys-Cys-Leu-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Lys-Arg-Asp-Leu-Gly-Trp.
Claim 3
Dependent Claim
23 words
The method of claim 1 wherein the CIF is a homodimer whose chains each have the amino acid sequence shown in FIG. 1.
Claim 4
Dependent Claim
16 words
The method of claim 1 wherein the CIF is substantially free of activating agent or co-factor.
Claim 5
Dependent Claim
10 words
The method of claim 1 wherein the inflammation is acute.
Claim 6
Dependent Claim
10 words
The method of claim 1 wherein the inflammation is chronic.
Claim 7
Dependent Claim
11 words
The method of claim 1 wherein the CIF is administered systemically.
Claim 8
Dependent Claim
11 words
The method of claim 1 wherein the CIF is administered locally.
Claim 9
Dependent Claim
15 words
The method of claim 1 wherein the inflammation involves the respiratory system of the patient.
Claim 10
Dependent Claim
15 words
The method of claim 8 wherein the CIF is administered to the patient by inhalation.
Claim 11
Dependent Claim
11 words
The method of claim 1 wherein the inflammation is dermal inflammation.
Claim 12
Dependent Claim
11 words
The method of claim 10 wherein the CIF is administered topically.
Claim 13
Dependent Claim
14 words
The method of claim 1 wherein the inflammation is associated with an autoimmune disease.
Claim 14
Dependent Claim
13 words
The method of claim 1 wherein the inflammation is in the gastrointestinal tract.
Claim 15
Dependent Claim
23 words
The method of claim 7 wherein the CIF is a homodimer whose chains each have the amino acid sequence shown in FIG. 1.
Claim 16
Dependent Claim
17 words
The method of claim 7 wherein the CIF is administered in combination with a pharmaceutically acceptable carrier.
Claim 17
Dependent Claim
28 words
The method of claim 15 wherein the carrier is a collagenous carrier and the weight ratio of CIF to carrier is in the range of 1:1000 to 1:20000.
Claim 18
Dependent Claim
16 words
The method of claim 7 wherein the CIF is substantially free of activation agent or cofactor.
Claim 19
Independent Claim
60 words
A method of preventing or reducing the local inflammatory response to a solid implant made of a permeable material comprising dispersing an anti-inflammatorily effective amount of a CIF in the material, wherein said CIF is a homodimer whose chains each have (a) the following partial N-terminal amino acid sequence: Ala-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Ser-Ser-thr-Glu-Lys-Asn-Cys-Cys-Val-Arg-Gln-Leu-Tjr-Ile-Asp-Phe-Arg-Lys-Asp-Leu-Gly-Trp-, or (b) the following partial N-terminal amino acid sequence: Ala-Leu-Asp-Ala-Ala-Tyr-Cys-Phe-Arg-Asn-Val-Gln-Asp-Asn-Cys-Cys-Leu-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Lys-Arg-Asp-Leu-Gly-Trp.
Claim 20
Independent Claim
60 words
A method of preventing or reducing the local inflammatory response to a solid implant made of a permeable material comprising dispersing an anti-inflammatorily effective amount of a CIF in the material, wherein said CIF is a homodimer whose chains each have (a) the following partial N-terminal amino acid sequence: Ala-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Ser-Ser-thr-Glu-Lys-Asn-Cys-Cys-Val-Arg-Gln-Leu-Tjr-Ile-Asp-Phe-Arg-Lys-Asp-Leu-Gly-Trp-, or (b) the following partial N-terminal amino acid sequence: Ala-Leu-Asp-Ala-Ala-Tyr-Cys-Phe-Arg-Asn-Val-Gln-Asp-Asn-Cys-Cys-Leu-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Lys-Arg-Asp-Leu-Gly-Trp.
Claim 21
Dependent Claim
23 words
The method of claim 18 wherein the CIF is a homodimer whose chains each have the amino acid sequence shown in FIG. 1.
Claim 22
Dependent Claim
16 words
The method of claim 18 wherein the CIF is substantially free of activating agent or cofactor.
Claim 23
Dependent Claim
15 words
The method of claim 18 wherein said amount is below that which promotes tissue deposition.
Claim 24
Dependent Claim
10 words
The method of claim 18 wherein the material is collagenous.
References Cited (Backward Citations)
US3400199A
Cited
US4394370A
Cited
WO1984001106A1
Cited
US4434094A
Cited
EP0128849A1
Cited
EP0269408A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-02-21 | 1992-08-22 | 1993-02-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-02-21 | 1996-08-22 | 1997-02-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-02-21 | 2000-08-22 | 2001-02-21 | $7700.00 | Window Closed / Lapsed |